All In Biotech

Drug Trial Radar · NCT05308225

Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

A Phase 1b/2a, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Apr 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

72

Actual

Start

Feb 1, 2023

Primary completion

Dec 2025

Study completion Jul 2026

Sponsor

Lead sponsor
Sorrento Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-stage phase 1b/2a, open-label, multicenter, dose-escalation study of STI-6129 administered intravenously once in a 4-week cycle in subjects with relapsed or refractory multiple myeloma.

Conditions

  • Multiple Myeloma

Interventions

  • STI-6129Biological

    Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of STI-6129Time frame: Baseline through study completion at up to approximately 24 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • NYU Lagone Health

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Gabrail Cancer Center

    Canton, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.